Long-lasting Subjective Effects of LSD in Normal Subjects

Overview

Journal Psychopharmacology (Berl)

Specialty Pharmacology

Date 2017 Sep 18

PMID 28918441

Citations 74

Authors

Yasmin Schmid

Matthias E Liechti

Affiliations

Soon will be listed here.

Abstract

Rationale: Lysergic acid diethylamide (LSD) and other serotonergic hallucinogens can induce profound alterations of consciousness and mystical-type experiences, with reportedly long-lasting effects on subjective well-being and personality.

Methods: We investigated the lasting effects of a single dose of LSD (200 μg) that was administered in a laboratory setting in 16 healthy participants. The following outcome measures were assessed before and 1 and 12 months after LSD administration: Persisting Effects Questionnaire (PEQ), Mysticism Scale (MS), Death Transcendence Scale (DTS), NEO-Five Factor Inventory (NEO-FFI), and State-Trait Anxiety Inventory (STAI).

Results: On the PEQ, positive attitudes about life and/or self, positive mood changes, altruistic/positive social effects, positive behavioral changes, and well-being/life satisfaction significantly increased at 1 and 12 months and were subjectively attributed by the subjects to the LSD experience. Five-Dimensions of Altered States of Consciousness (5D-ASC) total scores, reflecting acutely induced alterations in consciousness, and Mystical Experience Questionnaire (MEQ30) total scores correlated with changes in well-being/life satisfaction 12 months after LSD administration. No changes in negative attitudes, negative mood, antisocial/negative social effects, or negative behavior were attributed to the LSD experience. After 12 months, 10 of 14 participants rated their LSD experience as among the top 10 most meaningful experiences in their lives. Five participants rated the LSD experience among the five most spiritually meaningful experiences in their lives. On the MS and DTS, ratings of mystical experiences significantly increased 1 and 12 months after LSD administration compared with the pre-LSD screening. No relevant changes in personality measures were found.

Conclusions: In healthy research subjects, the administration of a single dose of LSD (200 μg) in a safe setting was subjectively considered a personally meaningful experience that had long-lasting subjective positive effects.

Trial Registration: Registration identification number: NCT01878942.

Citing Articles

Examining the Rationale for Studying Psychedelic-Assisted Psychotherapy for the Treatment of Caregiver Distress.

Gold N, Podrebarac S, White L, Marini C, Simon N, Mittelman M Psychedelic Med (New Rochelle). 2025; 1(2):87-97.

PMID: 40046728 PMC: 11658675. DOI: 10.1089/psymed.2022.0011.

Unveiling the Complexities of Medications, Substance Abuse, and Plants for Recreational and Narcotic Purposes: An In-Depth Analysis.

Predescu I, Jijie A, Patrascu D, Pasc A, Piros E, Trandafirescu C Pharmacy (Basel). 2025; 13(1).

PMID: 39998006 PMC: 11859396. DOI: 10.3390/pharmacy13010007.

Moderating factors in psilocybin-assisted treatment affecting mood and personality: A naturalistic, open-label investigation.

Irrmischer M, Puxty D, Yildirim B, Deijen J, Engelbregt H Psychopharmacology (Berl). 2025; 242(4):725-740.

PMID: 39775022 PMC: 11890248. DOI: 10.1007/s00213-024-06733-3.

The Psychedelic Renaissance: A Catholic Perspective.

Carroll T Linacre Q. 2024; :00243639241274818.

PMID: 39544399 PMC: 11559537. DOI: 10.1177/00243639241274818.

From antidepressants and psychotherapy to oxytocin, vagus nerve stimulation, ketamine and psychedelics: how established and novel treatments can improve social functioning in major depression.

Kupferberg A, Hasler G Front Psychiatry. 2024; 15:1372650.

PMID: 39469469 PMC: 11513289. DOI: 10.3389/fpsyt.2024.1372650.

References

Griffiths R, Johnson M, Richards W, Richards B, McCann U, Jesse R . Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology (Berl). 2011; 218(4):649-65. PMC: 3308357. DOI: 10.1007/s00213-011-2358-5. View

Strajhar P, Schmid Y, Liakoni E, Dolder P, Rentsch K, Kratschmar D . Acute Effects of Lysergic Acid Diethylamide on Circulating Steroid Levels in Healthy Subjects. J Neuroendocrinol. 2016; 28(3):12374. DOI: 10.1111/jne.12374. View

Dolder P, Schmid Y, Haschke M, Rentsch K, Liechti M . Pharmacokinetics and Concentration-Effect Relationship of Oral LSD in Humans. Int J Neuropsychopharmacol. 2015; 19(1). PMC: 4772267. DOI: 10.1093/ijnp/pyv072. View

Costa Jr P, McCrae R . Domains and facets: hierarchical personality assessment using the revised NEO personality inventory. J Pers Assess. 1995; 64(1):21-50. DOI: 10.1207/s15327752jpa6401_2. View

Studerus E, Kometer M, Hasler F, Vollenweider F . Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. J Psychopharmacol. 2010; 25(11):1434-52. DOI: 10.1177/0269881110382466. View

Krebs T, Johansen P . Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials. J Psychopharmacol. 2012; 26(7):994-1002. DOI: 10.1177/0269881112439253. View

Liechti M . Modern Clinical Research on LSD. Neuropsychopharmacology. 2017; 42(11):2114-2127. PMC: 5603820. DOI: 10.1038/npp.2017.86. View

Barrett F, Griffiths R . Classic Hallucinogens and Mystical Experiences: Phenomenology and Neural Correlates. Curr Top Behav Neurosci. 2017; 36:393-430. PMC: 6707356. DOI: 10.1007/7854_2017_474. View

Mueller F, Lenz C, Dolder P, Harder S, Schmid Y, Lang U . Acute effects of LSD on amygdala activity during processing of fearful stimuli in healthy subjects. Transl Psychiatry. 2017; 7(4):e1084. PMC: 5416695. DOI: 10.1038/tp.2017.54. View

10.

MacLean K, Johnson M, Griffiths R . Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. J Psychopharmacol. 2011; 25(11):1453-61. PMC: 3537171. DOI: 10.1177/0269881111420188. View

11.

Carbonaro T, Bradstreet M, Barrett F, MacLean K, Jesse R, Johnson M . Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. J Psychopharmacol. 2016; 30(12):1268-1278. PMC: 5551678. DOI: 10.1177/0269881116662634. View

12.

Griffiths R, Richards W, Johnson M, McCann U, Jesse R . Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J Psychopharmacol. 2008; 22(6):621-32. PMC: 3050654. DOI: 10.1177/0269881108094300. View

13.

Johnson M, Richards W, Griffiths R . Human hallucinogen research: guidelines for safety. J Psychopharmacol. 2008; 22(6):603-20. PMC: 3056407. DOI: 10.1177/0269881108093587. View

14.

Griffiths R, Johnson M, Carducci M, Umbricht A, Richards W, Richards B . Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol. 2016; 30(12):1181-1197. PMC: 5367557. DOI: 10.1177/0269881116675513. View

15.

Gasser P, Holstein D, Michel Y, Doblin R, Yazar-Klosinski B, Passie T . Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis. 2014; 202(7):513-20. PMC: 4086777. DOI: 10.1097/NMD.0000000000000113. View

16.

Nichols D . Psychedelics. Pharmacol Rev. 2016; 68(2):264-355. PMC: 4813425. DOI: 10.1124/pr.115.011478. View

17.

Garcia-Romeu A, Griffiths R, Johnson M . Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Curr Drug Abuse Rev. 2015; 7(3):157-64. PMC: 4342293. DOI: 10.2174/1874473708666150107121331. View

18.

Carhart-Harris R, Muthukumaraswamy S, Roseman L, Kaelen M, Droog W, Murphy K . Neural correlates of the LSD experience revealed by multimodal neuroimaging. Proc Natl Acad Sci U S A. 2016; 113(17):4853-8. PMC: 4855588. DOI: 10.1073/pnas.1518377113. View

19.

Pahnke W . Psychedelic drugs and mystical experience. Int Psychiatry Clin. 1969; 5(4):149-62. View

20.

Pahnke W, Kurland A, Unger S, Savage C, Grof S . The experimental use of psychedelic (LSD) psychotherapy. JAMA. 1970; 212(11):1856-63. View